BeOne Medicines (ONC) Retained Earnings (2015 - 2026)
BeOne Medicines (ONC) posted quarterly Retained Earnings of $12.9 billion for Q1 2026, up 5.38% year-over-year from $12.2 billion in Q1 2025, and up 255.13% quarter-over-quarter from -$8.3 billion in Q4 2025.
BeOne Medicines (ONC) Retained Earnings (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has reported Retained Earnings for 12 consecutive years, with $12.9 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 5.38% year-over-year to $12.9 billion; the TTM figure through Mar 2026 stood at $12.9 billion (up 5.38% YoY), while the FY2025 annual figure was -$8.3 billion, down 168.83% from the prior year.
- Retained Earnings advanced to $12.9 billion in Q1 2026 per ONC's latest filing, from -$8.3 billion in the prior quarter.
- Across five years, Retained Earnings topped out at $12.9 billion in Q1 2026 and bottomed at -$8.5 billion in Q2 2025.
- Historically, Retained Earnings has averaged $6.4 billion across 5 years, with a median of $11.5 billion in 2022.
- Annual changes were most pronounced in 2022 — Retained Earnings tumbled 781.69% — and 2023, when it soared 14353.51%.
- BeOne Medicines' Retained Earnings stood at $11.5 billion in 2022, then climbed by 0.5% to $11.6 billion in 2023, then gained by 4.22% to $12.1 billion in 2024, then tumbled by 168.83% to -$8.3 billion in 2025, then soared by 255.13% to $12.9 billion in 2026.
- Business Quant data shows ONC's Retained Earnings at $12.9 billion in Q1 2026, -$8.3 billion in Q4 2025, and $12.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 5.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.05 Bn |
| Mar 31, 2026 | 12.91 Bn |
| Dec 31, 2025 | -8.32 Bn |
| Sep 30, 2025 | 12.62 Bn |
| Jun 30, 2025 | -8.51 Bn |
| Mar 31, 2025 | 12.25 Bn |
| Dec 31, 2024 | 12.09 Bn |
| Sep 30, 2024 | -8.45 Bn |
| Jun 30, 2024 | 11.84 Bn |
| Mar 31, 2024 | -8.21 Bn |
| Dec 31, 2023 | 11.60 Bn |
| Sep 30, 2023 | 11.50 Bn |
| Jun 30, 2023 | 11.75 Bn |
| Mar 31, 2023 | 11.64 Bn |
| Dec 31, 2022 | 11.54 Bn |
| Sep 30, 2022 | 11.45 Bn |
| Jun 30, 2022 | -82.45 Mn |
| Mar 31, 2022 | 11.27 Bn |
| Dec 31, 2021 | 11.19 Bn |
| Sep 30, 2021 | 7.72 Bn |